Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Organisation › Details

Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)

Headquartered in Halle (Saale), Germany, Vivoryon Therapeutics AG (Euronext Amsterdam: currently PBD, to be changed to VVY) is a clinical stage precision medicine company focused on bringing first-in-class therapies to patients suffering from age-related diseases. The company has a successful track record in bringing drugs targeted to post-translational modifying enzymes to the market. Current projects are focusing on the two isoenzymes of Glutaminyl cyclase, QPCT and QPCTL. QPCT is the crucial enzyme for the generation of highly neurotoxic pyroglutamate species of Abeta. Its inhibition by Vivoryon’s lead molecule PQ912, has successfully completed a Phase 2a (SAPHIR) study and the Company has initiated a Phase 2b core program for the treatment of Alzheimer’s disease (AD). Whereas QPCTL has been identified as a potential target in cancer therapy. Blocking the enzymatic function of QPTCL by small molecule inhibitors is a novel therapeutic approach to silence the CD47/SIRP? signal in cancer immunotherapy. Vivoryon has a unique and exceptionally strong patent position on QPCT and QPCTL inhibitors. *

 

Period Start 2019-06-11 renamed
  Group Vivoryon (Group)
  Predecessor Probiodrug AG (Euronext Amsterdam: PBD)
Products Industry drug development technology
  Industry 2 QC inhibitor (glutam(in)yl cyclase inhibitor)
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Schäffer, Michael (Probiodrug 201810– CBO joined 201808 as EVP Business + Strategy before Crelux + Sireen)
     
Region Region Halle (Saale)
  Country Germany
  Street 22 Weinbergweg
  City 06120 Halle (Saale)
  Tel +49-345-55599-00
    Address record changed: 2019-07-13
     
Basic data Employees B: 11 to 50 (2019-06-30)
  Currency EUR
  Annual sales 44,000 (operating income (2015) 2015-12-31)
  Profit -13,891,000 (2016-12-31)
  Cash 9,300,000 (2018-03-31)
     
    * Document for �About Section�: Probiodrug AG. (6/12/19). "Press Release: Probiodrug AG Becomes Vivoryon Therapeutics AG". Halle (Saale).
     
   
Record changed: 2019-10-11

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Vivoryon (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top